LAVA Medtech Acquisition Corp. (NASDAQ:LVACU – Get Rating) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 200 shares, a growth of 100.0% from the March 15th total of 100 shares. Based on an average daily trading volume, of 4,700 shares, the short-interest ratio is presently 0.0 days.
Hedge funds have recently added to or reduced their stakes in the stock. Sage Mountain Advisors LLC bought a new position in LAVA Medtech Acquisition in the 4th quarter valued at approximately $175,000. Alliancebernstein L.P. bought a new position in LAVA Medtech Acquisition in the 4th quarter valued at approximately $248,000. LMR Partners LLP bought a new position in LAVA Medtech Acquisition in the 4th quarter valued at approximately $252,000. Calamos Advisors LLC bought a new position in LAVA Medtech Acquisition in the 4th quarter valued at approximately $262,000. Finally, Glazer Capital LLC bought a new position in LAVA Medtech Acquisition in the 4th quarter valued at approximately $323,000.
LVACU stock opened at $10.04 on Friday. LAVA Medtech Acquisition has a 12-month low of $9.89 and a 12-month high of $10.20. The company has a 50 day simple moving average of $10.11.
LAVA Medtech Acquisition Corp. intends to acquire assets and businesses through a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization. It focuses on pursuing opportunities in healthcare and healthcare-related industries primarily in the United States and Canada. The company was incorporated in 2021 and is based in Waltham, Massachusetts.
Read More
- Get a free copy of the StockNews.com research report on LAVA Medtech Acquisition (LVACU)
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- The Top Is In For Infosys
- 3 Stellar Steel Stocks to Buy Now
Receive News & Ratings for LAVA Medtech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Medtech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.